Consequently, qEEG and ERPs have gained renewed interest among those interested in discovering and developing novel therapies for several important reasons: (1) to establish central nervous system pharmacodynamic activity for novel compounds [36] and (2) to potentially yield noninvasive and relativelylow-cost biomarkers for key diseases, including AD.